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Abstract
Background: Therapeutic gene transfer affords a clinically feasible and safe approach to cancer
treatment but a more effective modality is needed to improve clinical outcomes. Combined
transfer of therapeutic genes with different modes of actions may be a means to this end.
Interleukin-12 (IL-12), a heterodimeric immunoregulatory cytokine composed of covalently linked
p35 and p40 subunits, has antitumor activity in animal models. The enzyme/prodrug strategy using
cytosine deaminase (CD) and 5-fluorocytosine (5-FC) has been used for cancer gene therapy. We
have evaluated the antitumor effect of combining IL-12 with CD gene transfer in mice bearing renal
cell carcinoma (Renca) tumors.
Methods: Adenoviral vectors were constructed encoding one or both subunits of murine IL-12
(Ad.p35, Ad.p40 and Ad.IL-12) or cytosine deaminase (Ad.CD). The functionality of the IL-12 or
CD gene products expressed from these vectors was validated by splenic interferon (IFN)-γ
production or viability assays in cultured cells. Ad.p35 plus Ad.p40, or Ad.IL-12, with or without
Ad.CD, were administered (single-dose) intratumorally to Renca tumor-bearing mice. The animals
injected with Ad.CD also received 5-FC intraperitoneally. The antitumor effects were then
evaluated by measuring tumor regression, mean animal survival time, splenic natural killer (NK) cell
activity and IFN-γ  production.
Results: The inhibition of tumor growth in mice treated with Ad.p35 plus Ad.p40 and Ad.CD,
followed by injection of 5-FC, was significantly greater than that in mice treated with Ad.CD/5-FC,
a mixture of Ad.p35 plus Ad.p40, or Ad.GFP (control). The combined gene transfer increased
splenic NK cell activity and IFN-γ  production by splenocytes. Ad.CD/5-FC treatment significantly
increased the antitumor effect of Ad.IL-12 in terms of tumor growth inhibition and mean animal
survival time.
Conclusion: The results suggest that adenovirus-mediated IL-12 gene transfer combined with
Ad.CD followed by 5-FC treatment may be useful for treating cancers.
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Background
Gene therapy for treating cancers has been intensively
investigated. Therapeutic gene transfer using viral or non-
viral vectors has been shown to be clinically feasible and
safe. However, the therapeutic outcome appears not to be
high as expected, presumably because the in vivo gene
delivery efficiency is low. In this sense, a more effective
modality is needed to improve the therapeutic benefit.
Combined transfer of genes with different mechanisms of
action may potentate the therapeutic outcome. Indeed,
combination cancer gene therapy using cytokine and sui-
cide genes has been shown to be more effective than sin-
gle gene transfer in animal models [1-9].
Interleukin (IL)-12 is a heterodimeric cytokine composed
of 35- and 40-kDa subunits, which are covalently linked
by a disulfide bond [10,11]. IL-12 stimulates interferon-γ
(IFN-γ ) production by natural killer (NK) cells, enhances
the cytolytic activities of NK cells and cytotoxic T lym-
phocytes (CTLs), stimulates the differentiation of Th1
cells and inhibits angiogenesis [12-14]. These biological
activities have provided a rationale for the use of IL-12 in
cancer immunotherapy. In fact, recombinant IL-12 (rIL-
12) exhibits significant antitumor activity in various ani-
mal models [12-14]. Subsequent phase I and II studies on
various cancer types using intravenous or subcutaneous
administration of human rIL-12 [15,16] showed some
beneficial responses, but there were also adverse effects,
which interrupted the clinical trials [17,18]. Recently, it
has been reported that intratumoral administration of rIL-
12 shows dose-limiting toxicity and results in measurable
locoregional immunological responses in head and neck
squamous cell carcinoma patients [19].
Since intratumoral IL-12 gene transfer could minimize the
adverse effects of systemic rIL-12 administration [17], the
effectiveness against tumors of cell vaccines expressing IL-
12, or viral or nonviral vectors encoding IL-12, has been
evaluated in various animal models [18,20-23]. The
results indicate that, compared to IL-2, IL-4, interferons,
and granulocyte-macrophage colony-stimulating factor,
IL-12 is one of the most effective immunomodulators for
cancer treatment [13,18,20,21,23]. Pilot clinical trials
have been conducted in patients with advanced primary
and metastatic liver cancer on the basis of these results
[24]. Intratumorally administered adenoviral vectors
expressing IL-12 had low efficacy but no cumulative toxic-
ity [24].
Suicide gene therapy deploys genes such as cytosine
deaminase (CD), herpes simplex or varicella zoster virus
thymidine kinase (TK), or nitroreductase, all of which
convert nontoxic prodrugs into cytotoxic agents [25-27].
Systemically administered prodrugs are converted to the
active agents only in cells expressing these suicide genes,
so the therapeutic effect is maximized while systemic tox-
icity is reduced. CD, which normally catalyzes the deami-
nation of cytosine to uracil during RNA biosynthesis, is
found in many bacteria and fungi but not in mammalian
cells [28-30]. It also deaminates 5-fluorocytosine (5-FC)
to 5-fluorouracil (5-FU), which is highly toxic to cells. 5-
FU has been used clinically since the late 1950s to treat
colorectal cancer [31]. A cellular metabolite of 5-FU, 5-
fluorouridine triphosphate, is incorporated into RNA in
place of UTP and consequently the multiple functions of
RNA are impaired. Another metabolite of 5-FU, 5-fluoro-
deoxyuridine monophosphate, blocks thymidylate syn-
thase activity and thus inhibits DNA synthesis.
No currently available gene delivery system can deliver
therapeutic genes including suicide genes to all the target
cells in vivo. However, tumor cells expressing a suicide
gene can kill neighboring tumor cells that do not express
this gene by the by-stander effect, which could partly over-
come the gene delivery problem [32-35]. A number of sui-
cide gene therapies have been shown to be effective
against various cancer cell lines in culture and in animal
models. Subsequent phase I, II or III studies using CD or
TK genes were performed in colorectal cancer patients
with liver metastases and in brain tumor patients [36-47].
The antitumor activities appeared less than expected [46],
but the results showed that suicide gene therapy is safe to
apply in the oncology clinic [36-47].
A combination of IL-2 and TK genes exerted a more potent
therapeutic outcome in a metastatic carcinoma model,
and induced antitumor immunity [1]. Since then, combi-
nation gene therapies using various cytokine and suicide
genes have been intensively investigated [2-9]. In the
present study, we investigated the effectiveness of com-
bined transfer of IL-12 and CD genes against renal cell car-
cinoma (Renca)-tumors in mice.
Methods
Cells and mice
HeLa, 293, Renca (a cell line spontaneously derived from
BALB/c renal cell adenocarcinoma), and NK cell-sensitive
YAC-1 cells were cultured in DMEM or RPMI-1640
medium (Gibco-BRL) supplemented with 10% fetal
bovine serum (FBS) and penicillin/streptomycin. Cultures
were maintained in a 5% CO2 atmosphere at 37°C.
Male or female wild-type BALB/c mice, 7–8 weeks of age,
were purchased from the animal breeding laboratory at
the Korea Research Institute of Bioscience and Biotechnol-
ogy. They were kept (five mice per cage) in isolation under
specific pathogen-free conditions, exposed to 12-h light/
12-h dark cycles, and provided with standard feed and
water ad libitum.BMC Cancer 2005, 5:51 http://www.biomedcentral.com/1471-2407/5/51
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Construction of replication-defective adenoviral vectors
cDNAs for Esherichia coli cytosine deaminase, p35 and/or
p40 murine IL-12 subunits [48] or green fluorescent pro-
tein (GFP) were inserted by a standard cloning procedure
into pX.dCMV.pA, an adeno-transfer plasmid harboring
the immediate early gene promoter from human cytome-
galovirus [49-51]. The shuttle plasmids were cotransfected
into 293 cells together with pJM17, which harbors the
genomic DNA of adenovirus 5 (Microbix, Canada), by a
standard calcium phosphate method. Primary plaques
were isolated and screened by PCR to ensure the presence
of the inserts. Positive clones were plaque-purified twice
and a single plaque was chosen for further amplification
in 293 cells. Recombinant adenoviruses were purified by
cesium chloride gradient centrifugation as previously
described [49-51], dialyzed to remove the cesium chloride
and frozen at -70°C.The viral titer was determined by a
293 plaque assay and expressed as plaque-forming units
(pfu).
Cell viability assay
HeLa cells were plated on 60-mm dishes at 5 × 105 cells/
plate and mock-transduced, or transduced with Ad.CD,
for 2 h at a multiplicity of infection (MOI) of 50 in serum-
free DMEM. Cultures were continued for a further 12 h.
Transduced and non-transduced cells were then mixed in
different ratios and incubated in 24-well dishes for 24 h.
The culture media were replaced with fresh media con-
taining various concentrations of 5-FC, and incubation
was continued for 4 days. Cell viability was assessed by
the trypan-blue exclusion assay.
Western blotting
HeLa cells were plated on 60-mm dishes at 5 × 105 cells/
dish and transduced with recombinant adenoviruses in
serum-free DMEM for 2 h. The culture media from mock-
or virus-transduced cells were retained for measurement
of released IL-12 at 48 h postinfection, and the cells were
harvested in a lysis buffer (10 mM Tris-HCl, pH 7.5, 10
mM NaCl, 1.5 mM MgCl2, 10 mM β -mercaptoethanol).
Cell extracts were prepared by three cycles of freezing (-
70°C) and thawing and precleared by centrifugation. Fifty
micrograms of precleared cell lysates were subjected to
SDS-10% polyacrylamide gel electrophoresis (PAGE). The
separated proteins were transferred to PVDF membranes,
which were blocked with 3% bovine serum albumin
(BSA) in phosphate-buffered saline (PBS) and incubated
with rat anti-mouse IL-12 antibody (PharMingen), then
with horseradish peroxidase-conjugated rabbit anti-rat
lgG antibody (Sigma). Proteins were detected according to
Amersham's ECL protocol. The culture supernatants were
incubated with anti-IL-12 antibody. A suspension of pro-
tein G-Sepharose beads (100 µl) was added and the incu-
bation mixtures were further incubated at 4°C for 12 h.
The immunoprecipitates were washed three times with 40
mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid, pH 7.4, 100 mM KCl, 0.1% NP-40, 0.1 mM DTT, and
once with PBS, then immunoblotted with the rat anti-
mouse IL-12 antibody described above.
Animal model and treatment
Tumors were generated on the flanks of BALB/c mice by
subcutaneous (s.c.) injection of 1.5 × 105 of Renca cells in
0.1 ml of PBS. After visible tumors had developed for 7–9
days after inoculation, the mice were injected once intra-
tumorally with recombinant adenoviruses at 1 × 109 pfu
in 10 mM Tris-HCl, pH 7.4, 1 mM MgCl2, 10% glycerol.
Animals undergoing 5-fluorocytosine therapy received
intraperitoneal administration of 5-FC (400 mg/kg) daily
for 10 days. Tumors were measured prior to virus injec-
tion and subsequently at intervals of 3 days. Linear cali-
pers were used to measure the longest diameter (a), width
(b), and depth (c). The tumor size was calculated by the
formula: (a × b × c/2).
ELISA for IFN-γ
ELISAs were performed using essentially the reagents and
procedures described in the Endogen (USA) product liter-
ature. Flat-bottomed 96-well microtiter plates (Nunc Max-
isorp) were coated with rat anti-IFN-γ  antibodies (1 µg/
ml) at 4°C overnight and blocked with 4% BSA in PBS for
2 h at 37°C. Renca cells were treated with mitomycin C at
50 µg/ml for 20 min at 37°C. Splenocytes (2 × 106 cells/
ml) obtained from the tumor-bearing mice 21 days after
virus treatment were stimulated with the inactivated
Renca cells in U-bottomed 96-well plates at an effector-to-
stimulator ratio of 10:1. Supernatants (50 µl) from 24 h
and 48 h cultures were added to the ELISA plate wells and
incubated for 1 h. After several washing steps, rat anti-
mouse IFN-γ  antibody conjugated with biotin was added.
Color was developed using avidin-conjugated horseradish
peroxidase and OPD substrate (Sigma). The reaction was
terminated by the addition of 2N H2SO4. The absorbance
was measured at 490 nm with an ELISA plate reader. The
amounts of IFN-γ  were quantified by interpolation of a
standard curve generated using known amounts of stand-
ard mouse rIFN-γ  (Endogen). The biological activity of the
IL-12 produced from the recombinant adenoviruses was
assessed on the basis of its ability to induce IFN-γ  secre-
tion from murine splenocytes. Murine splenocytes (1.5 ×
106 cells/well) were washed with cold medium and incu-
bated with the culture supernatants. IFN-γ  in the incuba-
tion media was then determined by an ELISA, as described
above.
Cytotoxicity assay of NK cells
The cytolytic activity of NK cells was determined by a
standard 4-h 51Cr-release assay. The spleens from dead
mice obtained 21 days after tumor inoculation were
removed aseptically and single-cell suspensions, preparedBMC Cancer 2005, 5:51 http://www.biomedcentral.com/1471-2407/5/51
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by passing the spleens through a metal mesh, were sus-
pended in 5 ml of 0.83% ammonium chloride to lyse the
red blood cells. The splenocytes were then used as effector
cells to assay NK cell activity. YAC-1 cells (2 × 106) in 0.5
ml of RPMI-1640 with 20% FBS were labeled with 50 µCi
of Na51CrO4 (Amersham) for 90 min. The labeled cells
were washed three times with serum-free DMEM and
mixed (1 × 104 per well) with the effector cells in a U-bot-
tomed 96-well plate for 4 h at 37°C at three different
effector-to-target ratios (100:1, 33:1, and 11:1), each in
triplicate. The mixtures of target and effector cells were
incubated for 4 h at 37°C. The percentage of specific 51Cr
release was calculated as [(cpm experimental release - cpm
spontaneous release/cpm maximum release - cpm sponta-
neous release)] × 100. The maximum 51Cr release was
determined from the supernatant when labeled cells were
lysed by adding 0.1 ml of 3% SDS. Spontaneous release
was determined from the supernatants after labeled cells
were incubated in 0.1 ml of medium without effector
cells. The standard deviations for each triplicate sample
and for spontaneous release were less than 10% and 20%,
respectively.
Statistics
Statistical analysis was carried out using the Student's t test
(unipolar, paired) and the chi-square test (two-tailed).
The values were considered statistically significant when
the P value was less than 0.05.
Results and discussion
Recombinant adenoviruses encoding the p35 and/or p40 
subunits of murine IL-12 express bioactive IL-12
We constructed replication-defective adenoviruses con-
taining the p35 and/or p40 subunits of murine IL-12
under the transcriptional control of the immediate early
gene promoter of human cytomegalovirus (Figure 1).
Ad.IL-12 contains murine cDNAs of both IL-12 subunits,
which are linked by an internal ribosome entry site
sequence from encephalomyocarditis virus. To test
whether Ad.p40 and Ad.IL-12 express the p40 subunit and
the p35-p40 heterodimer respectively, we transduced
HeLa cells with the two constructs at the indicated MOI.
Replication-defective adenovirus encoding GFP (Ad.GFP)
was used as a control. Lysates of cells transduced with
Ad.p40 or Ad.GFP were resolved by SDS-PAGE followed
by immunoblotting with anti-IL-12 antibody, which
reacts specifically with the p40 subunit of mouse IL-12
and with free p40 (Figure 2A, left panel). Ad.p40 was
found to express p40. The culture media from cells trans-
duced with Ad.IL-12 or Ad.GFP were immunoprecipitated
with anti-IL-12 antibody. The immuno-complexes were
resolved by SDS-PAGE under nonreducing conditions
and immunoblotted with anti-IL-12 antibody. The two
protein bands detected might be a p40 homodimer (p80)
and a p35-p40 heterodimer (p70) (Figure 2A, right panel,
indicated by arrows). Under nonreducing conditions,
Ad.IL-12 produced a doublet of 79/75 kDa that was sensi-
tive to a reducing agent [52]. Ad.p40 produces a band
migrating with an apparent molecular mass of approxi-
mately 90 kDa, which on a reducing gel reveals a band
consistent with the p40 monomer [53]. Thus, our result
appeared to be consistent with previous findings. We
could not assess p35 expression because no antibody spe-
cific for this subunit was available.
We next examined whether cells transduced with adenovi-
ruses encoding the p35 and/or p40 subunits release bioac-
tive IL-12. HeLa cells were mock-transduced, or
transduced with a 1:1 (pfu ratio) mixture of Ad.p35 and
Ad.p40, Ad.IL-12, or Ad.GFP at the indicated MOI, and
the culture supernatants were collected after 24 h incuba-
tion. Splenocytes from naïve mice were incubated with
equivalent volumes of the culture supernatants, and the
IFN-γ  contents of the medium were measured using ELISA
(Figure 2B and 2C). The culture supernatants from cells
transduced with a mixture of Ad.p35 and Ad.p40 or Ad.IL-
12 exhibited much higher IFN-γ  inducing-activity than the
controls. These results suggest that cells transduced with
Ad.p35 plus Ad.p40 or Ad.IL-12 release bioactive IL-12.
Recombinant adenovirus encoding cytosine deaminase 
(Ad.CD) expresses catalytically active cytosine deaminase
We constructed a replication-defective adenovirus encod-
ing cytosine deaminase (Figure 1). To examine whether
the Ad.CD virus expresses cytosine deaminase capable of
converting 5-FC to cytotoxic 5-FU, we transduced HeLa
cells with Ad.CD at an MOI of 50. Naïve HeLa or HeLa/
Schematic illustration of replication-defective adenoviral vec- tors constructed in this study Figure 1
Schematic illustration of replication-defective adenoviral vec-
tors constructed in this study. The E1 region of adenovirus 
type 5 (Ad 5) was replaced by the indicated genes under the 
transcriptional control of the immediate early gene promoter 
from human cytomegalovirus (pCMV). IRES; internal ribos-
omal entry sequence.
Ad.CD
Ad.p35
Ad.p40
Ad.IL-12
IL-12 p40 subunit
pCMV
Ad 5
IL-12 p35 subunit
E1
IL-12 p35 subunit IL-12 p40 subunit IRES
Cytosine deaminase (CD)BMC Cancer 2005, 5:51 http://www.biomedcentral.com/1471-2407/5/51
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CD cells, or mixtures of the two at the indicated ratios
(Figure 3), were incubated in culture media without or
with the indicated concentrations of 5-FC for 4 days, and
cell viability was assessed by the trypan-blue exclusion
assay (Figure 3). In the presence of 5-FC, the viability of
the HeLa/CD cells decreased markedly but the naïve HeLa
cells were unaffected, suggesting that cytosine deaminase
was expressed in the virus-transduced cells and metabo-
lized 5-FC to 5-FU. The viability of the mixtures of naïve
and HeLa/CD cells appeared to decrease more than the
proportion of naïve cells in the mixtures, particularly with
500 µg/ml 5-FC. Thus, the Ad.CD virus appeared to exert
a bystander effect, though not a drastic one. The results
suggest that Ad.CD expresses catalytically active cytosine
deaminase.
Transfer of the IL-12 and cytosine deaminase genes in 
combination, followed by 5-FC treatment, exerts potent 
antitumor activity in Renca-tumor bearing mice
Renca-tumor bearing mice were established as described
in the Methods section, randomly divided into 4 groups,
and injected once intratumorally with Ad.GFP, Ad.CD/5-
FC, Ad.p35 plus Ad.p40, or Ad.p35 plus Ad.p40 plus
Ad.CD. Mice receiving Ad.CD were treated with 5-FC.
Tumor growth was measured at the indicated times (Fig-
ure 4A). Mouse survival until day 42 was recorded (Figure
4B). The treatment outcomes are summarized in Table 1.
Inhibition of tumor growth was most marked in mice
treated with Ad.p35 plus Ad.p40 plus Ad.CD/5-FC (p <
The recombinant adenoviruses encoding murine p35 and/or  p40 subunits express biologically active IL-12 Figure 2
The recombinant adenoviruses encoding murine p35 and/or 
p40 subunits express biologically active IL-12. (A) HeLa cells 
were transduced with Ad.GFP, Ad.p40, or Ad.IL-12 at the 
indicated MOIs. Cells or culture media were harvested 48 h 
after transduction. Cleared lysates of cells transduced with 
Ad.GFP or Ad.p40 were immunoblotted with anti-IL-12 anti-
body (left panel). The culture media from HeLa cells trans-
duced with Ad.IL-12 or Ad.GFP were immunoprecipitated 
with anti-IL-12 antibody. The immunoprecipitates were dis-
solved in SDS sample buffer without reducing agent and sub-
jected to SDS-PAGE, followed by immunoblotting with anti-
IL-12 antibody (right panel). Molecular size markers in kilo-
daltons are shown at the left. The positions of p40, p35–p40 
heterodimer (p70) and p40 homodimer (p80) are indicated 
by arrows. (B and C) HeLa cells were mock-transduced or 
transduced with either a 1:1 (pfu ratio) mixture of Ad.p35 
and Ad.p40, or Ad.IL-12, or Ad.GFP, at the indicated MOI. 
Splenocytes from naïve mice were incubated with the culture 
supernatants for 24 h. ELISA was performed to determine 
the IFN-γ  levels after incubation. Data are means ± SD of 
two independent experiments, each performed in duplicate.
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Ad.CD virus expresses functional cytosine deaminase Figure 3
Ad.CD virus expresses functional cytosine deaminase. HeLa 
cells were transduced with Ad.CD at an MOI of 50 and incu-
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then treated with 5-FC at the indicated concentrations for 4 
days. Cell viability was assessed by the trypan-blue exclusion 
assay. Data are means ± SD of two independent experi-
ments, each performed in duplicate.
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0.001 for Ad.p35 plus Ad.p40 plus Ad.CD/5-FC vs Ad.GFP
and p < 0.0053 for Ad.p35 plus Ad.p40 plus Ad.CD/5-FC
vs Ad.CD/5-FC). The mean survival times were for 33.2 ±
10.4 days for Ad.p35 plus Ad.p40 plus Ad.CD/5-FC group
and 27.2 ± 10.9 days for Ad.p35 plus Ad.p40 group; the
difference is statistically significant (p < 0.0018). Among
the 15 mice treated with Ad.p35 plus Ad.p40 plus Ad.CD/
5-FC, four became tumor-free and four exhibited partial
The antitumor activity effected by IL-12 gene transfer increases in vivo when combined with cytosine deaminase/5-FC Figure 4
The antitumor activity effected by IL-12 gene transfer increases in vivo when combined with cytosine deaminase/5-FC. (A) Renca 
tumors were established in BALB/c mice by s.c. inoculation of 1.5 × 105 cells. When the tumors reached 5–6 mm diameter, the 
animals were randomly divided into four treatment groups (n = 15 per group) and injected once intratumorally with (1) Ad.p35 
(2.5 × 108 pfu) plus Ad.p40 (2.5 × 108 pfu) plus Ad.CD (5 × 108 pfu), or (2) Ad.p35 (5 × 108 pfu) and Ad.p40 (5 × 108 pfu), or (3) 
Ad.CD (1 × 109 pfu), or (4) Ad.GFP (1 × 109 pfu). Mice treated with Ad.CD were given 5-FC (400 mg/kg) intraperitoneally daily 
for 10 days. Graphic representations of mean tumor growth rates are shown. Bars indicate SD. (B) Mouse survival until day 42 
was recorded. Mice were sacrificed and considered as death when tumor size exceeded 1.5 cm in long and short axes. The 
mean survival times (± SD) were 33.2 ± 10.4 days for (1) group, 27.2 ± 10.9 days for (2) group, 21.9 ± 9.1 days for (3) group, 
and 19.7 ± 7.1 days for (4) group. The difference between (1) and (2) groups was statistically significant (p < 0.0018) by Stu-
dent's t test. The treatment outcome is summarized in Table 1. One animal in each of the groups treated with Ad.CD and 
Ad.GFP succumbed to toxicity, and two mice in the group treated with Ad.p35 plus Ad.p40 were excluded owing to peritoneal 
metastasis.
Table 1: Tumor regression following intratumoral injection of Ad.p35 plus Ad.p40, or Ad.CD/5-FC alone, or a combination of both
Treatment Response (%)
N Complete Partial Death or peritoneal 
metastasis
None
Ad.p35 + Ad.p40 + Ad.CD/5-FC 15 4 (27) 4 (27) 0 (0) 7 (46)
Ad.p35 + Ad.p40 15 1 (7) 2 (14) ‡2 (13) 10 (66)
Ad.CD/5-FC 15 1 (7) 0 (0) †1 (7) 13 (86)
Ad.GFP 15 0 (0) 0 (0) †1 (7) 14 (93)
N = number of Renca tumor-bearing mice injected once intratumorally with adenoviral vectors at the doses indicated in Figure 4 legend.
"Complete" refers to animals undergoing total and permanent regression of the injected tumor.
"Partial" refers to animals undergoing partial tumor regression followed by regrowth, or a significant delay in growth
"Death or peritoneal metastasis" refers to animals that died or had peritoneal metastasis during the period of investigation.
None refers to animals whose tumors have continued to grow at a rate comparable to controls.
†Death probably by toxicity.
‡Excluded due to peritoneal metastasis during the experiment.
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responses (Table 1). Among the 15 mice treated with
Ad.p35 plus Ad.p40, one became tumor-free and two
showed partial responses (p < 0.0464 for comparison of
the two treatments). Ad.p35 plus Ad.p40 treatment
appeared to be more effective than Ad.CD/5-FC, which
had a modest antitumor effect compared to the control
(Ad.GFP).
IL-12 and cytosine deaminase genes in combination, 
followed by 5-FC treatment, enhance the cytolytic activity 
of NK cells and increase IFN-γ  production
We examined whether the increased antitumor activity of
Ad.p35 plus Ad.p40 plus Ad.CD/5-FC (Figure 4) was asso-
ciated with the induction of tumor-specific CTLs, activa-
tion of NK cells, and induction of Th1 cytokines such as
IL-2 and IFN-γ . Effector cells were prepared from the
splenocytes of tumor-bearing mice treated with the
recombinant adenoviruses. Renca cells labeled with 51Cr
were used as target cells. A standard 4-h 51chromium
release assay was carried out. However, we did not detect
specific lysis of the labeled Renca cells (data not shown).
We performed an NK cell assay using the splenocytes as
effector cells and YAC-1 cells labeled with 51Cr as target
cells (Figure 5A). The effector cells from mice treated with
Ad.p35 plus Ad.p40 plus Ad.CD/5-FC lysed the target cells
about 10- and 5-fold more effectively than Ad.CD/5-FC
and Ad.GFP, respectively, at a 100:1 effector-to-target cell
ratio. Although Ad.p35 plus Ad.p40 treatment also
increased NK cell activity compared to Ad.CD/5-FC or
Ad.GFP, the cytolytic activity of splenic NK cells from
mice treated with this mixture was lower than that from
mice treated with Ad.p35 plus Ad.p40 plus Ad.CD/5-FC.
The effector cells used in the NK cell assay were mainly
splenocytes from mice in which the tumors were com-
pletely regressed or small. This may account for the
increased NK cell activity in the Ad.p35 plus Ad.p40 plus
Ad.CD/5-FC treatment group compared to the Ad.p35
plus Ad.p40 treatment group.
We next examined whether the virus treatments induced
Th1 cytokines, which may represent innate and/or adap-
tive immune responses. Splenocytes from tumor-bearing
mice treated with the viruses were incubated with inacti-
vated Renca cells. The IL-2 and IFN-γ  contents of the cul-
ture supernatants were measured by ELISA 24 and 48 h
after incubation, respectively. We detected no IL-2
induction in splenocytes from any of the treatment groups
(data not shown). However, IFN-γ  production was about
twice as great in splenocytes from mice treated with
Ad.p35 plus Ad.p40 plus Ad.CD/5-FC as in those treated
with Ad.CD/5-FC or Ad.GFP (Figure 5B, p < 0.0179 and <
0.0394 for Ad.p35 + Ad.p40 + Ad.CD/5-FC vs Ad.GFP and
Ad.CD/5-FC, respectively). Ad.p35 plus Ad.p40 treatment
also increased IFN-γ , but its effectiveness was significantly
less than that of Ad.p35 plus Ad.p40 plus Ad.CD/5-FC (p
< 0.0076). The results suggest that Ad.p35 plus Ad.p40
treatment, but not Ad.CD/5-FC, may enhance NK cell
IL-12 gene transfer combined with Ad.CD/5-FC increases  splenic NK cell activity and IFN-γ  production Figure 5
IL-12 gene transfer combined with Ad.CD/5-FC increases 
splenic NK cell activity and IFN-γ  production. (A) Cytotoxic-
ity of NK cells in Renca tumor-bearing mice treated with var-
ious adenoviral vectors (see Figure 4 legend). Mice in which 
tumor growth was completely or partially inhibited were 
chosen from the treatment groups on day 21 after tumor cell 
inoculation. Splenocytes were isolated from the treated mice 
(n = 3 per group) and used as effector cells. A standard 4-h 
51Cr release assay was performed using YAC-1 cells labeled 
with 51Cr as target cells. The percentage specific lysis was 
determined. Data are means ± SD. (B) Mouse splenocytes (n 
= 3 per group) were isolated from the treatment groups on 
day 21 as described above, and incubated with Renca cells 
inactivated by pretreatment with 50 µg/ml mitomycin C for 
20 min at 37°C. Culture supernatants were obtained from 
the incubated cells at the indicated times. Amounts of IFN-γ  
in the supernatants were measured using ELISA. Bars repre-
sent mean ± SD.
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activity and stimulate IFN-γ  production. Thus, the
enhancement of NK cell activity may be partially respon-
sible for the inhibition of tumor growth by treatment with
Ad.p35 plus Ad.p40 plus Ad.CD/5-FC or with Ad.p35 plus
Ad.p40.
The rapid tumor cell killing effect induced by suicide gene
products induces a strong antitumor immune response,
such as induction of tumor-specific CTLs and increased
NK cell activity [54-57]. However, we detected neither a
tumor-specific T cell immune response nor an enhanced
NK cell activity after Ad.CD/5-FC treatment alone. It is
possible that the antitumor activity of the Ad.CD con-
structed here was so weak that the tumor cells were not
killed rapidly (Figure 4). However, this is unlikely,
because Ad.CD/5-FC treatment increased the antitumor
activity of Ad.IL-12 (see Figure 6B and 6C). Alternatively,
the bystander effect, which kills neighboring tumor cells
not expressing suicide genes, may have exerted a negative
effect on the generation of tumor-specific CTL and/or
active NK cells. Immune cells or antigen-presenting cells
located close to the tumor cells could have taken up, and
been killed by, the toxic metabolites generated by the sui-
cide gene products. This may explain why the NK cell
activity in Ad.CD-treated mice was significantly lower
than in Ad.GFP-treated mice (Figure 5A, p < 0.001).
Transfer of the cytosine deaminase gene followed by 5-
FC treatment increases the antitumor effectiveness of IL-
12 gene transfer in Renca-tumor bearing mice
Since a mixture of Ad.p35 and Ad.p40 was used in previ-
ous experiments (Figure 4), we examined whether Ad.IL-
12, containing p35 and p40 in a single adenoviral vector
(Figure 1), was more effective against the tumors when
combined with Ad.CD/5-FC. Renca-tumor bearing mice
were divided randomly into four groups, treated intratu-
morally with (1) Ad.IL-12 plus Ad.CD/5-FC, (2) Ad.IL-12,
(3) Ad.CD/5-FC, or (4) Ad.GFP (control). Tumor sizes
were measured at the indicated times (Figure 6A). There
was a significant inhibition of tumor growth in mice
treated with Ad.IL-12 plus Ad.CD/5-FC compared to
Ad.GFP (p < 0.0456). The effectiveness of Ad.IL-12 (5 ×
108 pfu) plus Ad.CD/5-FC (5 × 108 pfu) appeared to be
similar to that of Ad.IL-12 (1 × 109 pfu) alone. This con-
trasts with the effectiveness of Ad.p35 plus Ad.p40 plus
Ad.CD/5-FC as compared to Ad.p35 plus Ad.p40 (Figure
4). Presumably the in vivo gene delivery of the Ad.p35-
Ad.p40 mixture was not so efficient as that of Ad.IL-12.
We further examined whether CD gene transfer followed
by 5-FC treatment increased the antitumor effectiveness of
IL-12 gene transfer. Sixteen Renca tumor-bearing mice
were divided into 2 groups. Since a higher dose than 1 ×
109 pfu of adenoviral vector appeared to be toxic to the
mice, the total dose given was 1 × 109 pfu. Mice in each
CD gene transfer followed by 5-FC treatment increases the  antitumor effectiveness of IL-12 gene transfer Figure 6
CD gene transfer followed by 5-FC treatment increases the 
antitumor effectiveness of IL-12 gene transfer. (A) Mice with 
tumors were established by subcutaneous inoculation of 1.5 
× 105 cells of Renca. The experimental animals in which 
tumors reached a diameter of about 5 mm were randomly 
divided into 4 treatment groups (n = 7 per group) and 
injected once intratumorally (day 0) with Ad.IL-12 (5 × 108 
pfu) plus Ad.CD (5 × 108 pfu), or 1 × 109 pfu of Ad.IL-12, or 
Ad.CD, or Ad.GFP. Mice treated with Ad.CD were given 
intraperitoneal 5-FC (400 mg/kg) daily for 10 days. Tumor 
growth was measured at intervals of three days until day 21. 
Graphic representations of mean tumor growth rates are 
shown. (B) and (C) Renca tumor-bearing mice were divided 
into two groups (n = 8 per group), which received single 
intratumorally injections (day 0) of Ad.IL-12 (5 × 108 pfu) plus 
Ad.CD (5 × 108 pfu) or Ad.IL-12 (5 × 108 pfu) plus Ad.GFP (5 
× 108 pfu). Mice in both groups were given intraperitoneal 5-
FC (400 mg/kg) daily for 10 days. Tumor growth was meas-
ured at the indicated times until day 25. Graphic representa-
tions of mean tumor growth rates are shown (B). Mouse 
survival until day 88 was recorded (C). The mean survival 
times (± SD) were 80.5 ± 20.8 days for the Ad.IL-12 plus 
Ad.CD/5-FC group and 67.3 ± 28.3 days for the Ad.IL-12 
plus Ad.GFP/5-FC group. The difference between these 
mean survival times was statistically significant (p < 0.0368) 
by Student's t test.
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group received Ad.IL-12 (5 × 108 pfu) with either Ad.CD
(5 × 108 pfu) or Ad.GFP (5 × 108 pfu) as a control. Both
groups were treated with 5-FC for 10 days. Tumor sizes
were measured at the indicated times (Figure 6B). Com-
bined transfer of the IL-12 and CD/5-FC genes resulted in
significant inhibition of tumor growth compared to IL-12
gene transfer alone (p < 0.0301). Six of the 8 mice treated
with Ad.IL-12 plus Ad.CD/5-FC, but only 4 of the 8 mice
treated with Ad.IL-12 plus Ad.GFP/5-FC, became tumor-
free and survived at 88 days. The mean survival times were
80.5 ± 20.8 days for the Ad.IL-12 + Ad.CD/5-FC group and
67.3 ± 28.3 days for the Ad.IL-12 + Ad.GFP/5-FC group;
the difference is statistically significant (p < 0.0368).
Conclusion
Among various cancer gene therapies, immunogene ther-
apy is a promising but challenging modality. Recent clin-
ical trials using Ad.IL-12 have shown that intratumoral IL-
12 gene transfer is a feasible and well-tolerated procedure
but exerts only mild antitumor effects [24]. An increased
Ad.IL-12 dose may increase the antitumor efficacy but
might entail a systemic, toxic effect that would limit the
use of Ad.IL-12 alone. In this study we have attempted to
improve the antitumor efficacy in Renca tumor-bearing
mice by using adenoviral vectors to transfer the IL-12 gene
in combination with cytosine deaminase, followed by 5-FC
treatment. The results show a marked inhibition of tumor
growth and significant prolongation of survival time, sug-
gesting that IL-12 plus CD gene transfer followed by 5-FC
treatment may be an alternative modality for the human
cancer treatment.
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